Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- (-) Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- (-) Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- (-) Value-Based Insurance Design
- Value Assessment
- (-) Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Audience
Display Only
Showing 49 Results
Value Assessments Should Encompass More Than Just Medicines
NPC submitted comments to the Institute for Clinical and Economic Review in response to its request for non-drug assessment topics, noting that value assessments should encompass more than just…
Concerns Raised About ICER’s Adapted Value Assessment Methods for High-Impact ‘Single and Short-term Therapies’
NPC outlines concerns with ICER's final adaptations to its value assessment framework for use when reviewing curative therapies.
NPC Analysis Compares, Contrasts 7 U.S. Value Assessment Frameworks
The National Pharmaceutical Council (NPC) today released an analysis of seven U.S. value assessment frameworks, comparing and contrasting the strengths and limitations associated with each framework…
Are Value Assessment Frameworks Ready for Prime Time?
An analysis from NPC, published in Value in Health, examined efforts from three organizations actively conducting value assessments.
NPC in AJMC: Why We Need Multiple Measures of Cost-Effectiveness in the US
In an editorial for The American Journal of Managed Care, NPC Chief Science Officer and Executive Vice President Dr. Robert Dubois explores the pitfalls of assigning only one organization the…
Rethinking Our Approach to Value Assessment to Ensure the Patient Voice is Heard
According to a panel at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Summit 2018 and summarized this week in Value in Health, even though value assessment frameworks…
NPC Outlines Ways to Make ICER’s Value Assessment Framework More Patient-Centered
NPC submitted comments to the Institute for Clinical and Economic Review (ICER) on ways to improve its value assessment framework and ensure that patient concerns are better addressed in treatment…
Access to Care: Development of a Medication Access Framework for Quality Measurement
A new framework, developed by the Pharmacy Quality Alliance (PQA) and supported by the National Pharmaceutical Council (NPC), identified seven main areas patients encounter while seeking access to…
Integrating Data for Better Care Management
To accelerate the ability of care management programs to use data to combat rising health care costs, while ensuring patient access to innovative treatments that can improve outcomes, NPC sponsored…
Personalized Medicine in a World of Value Frameworks
In a commentary published in the Journal of Clinical Pathways, NPC's Dr. Robert W. Dubois explores how to improve value frameworks’ approach to personalized medicine.
Growing Questions About Frameworks Highlight Need for Guiding Practices for Value Assessment
For several years, NPC has kept a close eye on value assessment frameworks and engaging with developers on ways to improve their methodologies, involve patient organizations and use a broad range of…
Amplifying the Migraine Community Voice in ICER Value Assessment Process
In an interview with NPC, Lindsay Videnieks, director of the Headache and Migraine Policy Forum (HMPF), discusses the kind of effort it takes to become involved in the ICER value assessment process,…
Could expanding pre-deductible coverage help those with chronic conditions?
According to a new issue brief from VBID Health, providing pre-deductible coverage for medicines used to treat common chronic conditions could lower out-of-pocket costs and increase medication…
A Precision Paradigm for Value Assessment: How Frameworks Can Account for Personalized Medicine to Inform Payers, Providers, Innovators and Patients
Personalized Medicine Coalition Senior Vice President of Science Policy Daryl Pritchard, PhD, explores personalized medicine and value assessment frameworks.
Considerations When Using ICER's Value Assessments
This week we read with great interest an article posted on the Health Affairs Blog that directly responded to National Pharmaceutical Council Chief Science Officer Dr. Robert Dubois’ Sept. 17…
Why the VA Should Proceed with Caution on ICER Collaboration
In a new blog published by Health Affairs, NPC Chief Science Officer and Executive Vice President Robert W. Dubois, MD, PhD, expands on our initial thoughts on the collaboration between the Institute…
Will Value Assessment Frameworks Promote Health Value and Access for Veterans?
NPC expressed concerns about the partnership between the Institute for Clinical and Economic Review and the U.S. Department of Veterans Affairs Pharmacy Benefits Management Services office to…